CD22 and B-cell non-Hodgkin lymphoma: Krauss et al. [36] have successfully generated a fusion of an anti-CD22 scFv to human Ang, which selectively targets and depletes malignant C22-positive B-cell lymphoma with an IC50 of 56 nmol/L.